Edgar Filing: Sharp Shalini - Form 4

Washington, D.C. 20549Check this box if no longer subject to Section 16.STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES								OMB Number: Expires: Estimated a burden hour response			
(Print or Type	Responses)										
Sharp Shalini S			Symbol	2. Issuer Name and Ticker or Trading Symbol ANTIGENICS INC /DE/ [AGEN]				5. Relationship of Reporting Person(s) to Issuer (Check all applicable)			
(Last)	Check					c all applicable)					
				onth/Day/Year) 26/2010				Director 10% Owner X Officer (give title Other (specify below) CFO			
				endment, Date Original nth/Day/Year)				6. Individual or Joint/Group Filing(Check Applicable Line) _X_ Form filed by One Reporting Person			
NEW YORK, NY 10010											
(City)	(State)	(Zip)	Tabl	le I - Non-D	Derivative	Secu	rities Acq	uired, Disposed of,	, or Beneficiall	y Owned	
1.Title of Security (Instr. 3)	2. Transaction E (Month/Day/Ye	ar) Executio any	med on Date, if Day/Year)	3. Transactio Code (Instr. 8)	(Instr. 3,	(A) or	d of (D) 5)	5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)	
Common	04/26/2010			Code V $A(1)$	3,750	(D) A	Price \$ 1.19	240,818	D		
Stock					,						
Common Stock	04/27/2010			S <u>(2)</u>	1,950	D	\$ 1.1601	238,868	D		

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.

Edgar Filing: Sharp Shalini - Form 4

 Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned

 (e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transactio Code (Instr. 8)	5. orNumber of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4, and 5)	;	Date	Amou Unde Secur	le and unt of rlying rities . 3 and 4)	8. Price of Derivative Security (Instr. 5)	9. Nu Deriv Secur Bene Owno Follo Repo Trans (Instr
				Code V	(A) (D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares		

Reporting Owners

Reporting Owner Name / Address	Relationships						
	Director	10% Owner	Officer	Other			
Sharp Shalini C/O ANTIGENICS INC. 162 FIFTH AVE., SUITE 900 NEW YORK, NY 10010			CFO				
Signatures							
Christine M. Klaskin, by Power Attorney	of	04/2	28/2010				
** Signature of Reporting Person			Date				

Explanation of Responses:

- * If the form is filed by more than one reporting person, *see* Instruction 4(b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
- (1) Represents settlement of restricted stock awarded on January 26, 2010.
- (2) Represents only shares sold to cover minimum federal, state, and local tax withholding requirements upon the vesting of the restricted shares awarded on January 26, 2010. This sale was made through a Rule 10b5-1 trading plan.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, *see* Instruction 6 for procedure. Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.